--- title: "Citigroup raises the target price of Beigene to $430, rating it as \"Buy\"" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/277401095.md" description: "Citi raised the target price for Beigene to $430, with a rating of \"Buy.\" The report pointed out that Beigene will continue to maintain its dominance in the chronic lymphocytic leukemia field and is expected to expand its market share. Total revenue is expected to reach $5.3 billion by 2025, with free cash flow of approximately $942 million. Management's revenue guidance for 2026 is between $6.2 billion and $6.4 billion, indicating strong growth potential" datetime: "2026-03-02T03:09:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277401095.md) - [en](https://longbridge.com/en/news/277401095.md) - [zh-HK](https://longbridge.com/zh-HK/news/277401095.md) --- > 支持的语言: [English](https://longbridge.com/en/news/277401095.md) | [繁體中文](https://longbridge.com/zh-HK/news/277401095.md) # Citigroup raises the target price of Beigene to $430, rating it as "Buy" Citi published a report expecting BeiGene (06160.HK) to maintain its dominant position in the field of chronic lymphocytic leukemia and to expand its market share this year compared to existing competitors. The bank has high hopes for the zanu and sonro combination based on strong early data, anticipating that this combination therapy will dominate the fixed regimen market that BeiGene has not yet entered, potentially capturing market share from regimens containing vene. The bank pointed out that notable catalysts in 2026 include the potential launch of sonro in the first half of the year in the United States for the treatment of relapsed/refractory mantle cell lymphoma, as well as data on BTK degraders for the treatment of relapsed/refractory chronic lymphocytic leukemia in the second half of the year, which may lead to an accelerated approval application submission by the end of 2026 or early 2027. BeiGene's total revenue for 2025 is expected to be approximately $5.3 billion, reaching the upper limit of the guidance range of $5.1 billion to $5.3 billion, exceeding both Citi's and market expectations. The annual free cash flow is expected to be around $942 million, an increase of approximately $1.6 billion year-on-year, demonstrating impressive cash generation capability. Management's guidance for total revenue this year is between $6.2 billion and $6.4 billion, which, at the median, implies a year-on-year growth of about 19%. Although market expectations are at the upper limit of the guidance range, which may put pressure on the stock price, the bank believes the guidance is reasonable and consistent with very strong growth. The bank raised BeiGene's (ONC.US) target price for U.S. stocks from $405 to $430, with a rating of "Buy." ### 相关股票 - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-CN/quote/560600.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-CN/quote/159615.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-CN/quote/159929.CN.md) - [BEONE MEDICINES (06160.HK)](https://longbridge.com/zh-CN/quote/06160.HK.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-CN/quote/159102.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-CN/quote/589720.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md) - [BeOne Medicines (688235.CN)](https://longbridge.com/zh-CN/quote/688235.CN.md) ## 相关资讯与研究 - [Qyuns Therapeutics' Arthritis Drug Crusekitug Accepted for Review in China; Shares Jump 11%](https://longbridge.com/zh-CN/news/278491064.md) - [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/zh-CN/news/278376120.md) - [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-CN/news/278445287.md) - [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/zh-CN/news/277818646.md) - [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/zh-CN/news/277695972.md)